Contribution of clinical trials to gross domestic product in Hungary

Croat Med J. 2014 Oct;55(5):446-51. doi: 10.3325/cmj.2014.55.446.


Aim: To determine the contribution of clinical trials to the gross domestic product (GDP) in Hungary.

Methods: An anonymous survey of pharmaceutical companies and clinical research organizations (CROs) was conducted to estimate their clinical trial-related employment and revenues. Clinical trial documents at the National Institute of Pharmacy (NIP) were analyzed to estimate trial-related revenues at health care institutions and the value of investigational medical products (IMPs) based on avoided drug costs. Financial benefits were calculated as 2010 US $ purchasing power parity (PPP) values.

Results: Clinical trials increased the revenue of Hungarian health care providers by 1 US $65.6 million. The value of IMPs was US $67.0 million. Clinical trial operation and management activities generated 900 jobs and US $166.9 million in revenue among CROs and pharmaceutical companies.

Conclusions: The contribution of clinical trials to the Hungarian GDP in 2010 amounted to 0.2%. Participation in international clinical trials may result in health, financial, and intangible benefits that contribute to the sustainability of health care systems, especially in countries with severe resource constraints. Although a conservative approach was employed to estimate the economic benefits of clinical trials, further research is necessary to improve the generalizability of our findings.

MeSH terms

  • Clinical Trials as Topic / economics*
  • Economics, Pharmaceutical*
  • Gross Domestic Product*
  • Health Personnel / economics*
  • Humans
  • Hungary